New Study Demonstrates AliveCor’s KardiaMobile 6L Significantly Increases Arrhythmia Detection Beyond Traditional Ambulatory Monitoring
A new study published in JACC Advances indicates that the KardiaMobile 6L device significantly improves arrhythmia detection compared to traditional monitoring methods. The research suggests that patient-initiated, symptom-triggered ECG recordings provide a higher diagnostic yield for cardiac conditions.
Why it matters
This study supports the shift toward patient-empowered, AI-driven diagnostic tools in cardiology, potentially improving early detection of heart conditions.
Peer-reviewed research in JACC Advances reveals patient-initiated, symptom-triggered 6-lead ECG monitoring nearly doubles the diagnostic yield of conventional continuous monitoring modalities
MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- AliveCor, the global leader in AI-powered cardiology, today announced a new prospective cohort study (the M-KEEPS study) conducted by researchers at the University of Rochester Clinical Cardiovascular Research Center and published in JACC Advances . The study, titled "Symptom-Triggered 6-Lead ECG Monitoring Significantly Increases Arrhythmia Detection Beyond Traditional Ambulatory Monitoring," establishes that 30-day use of the handheld KardiaMobile 6L (KM6L) device outperforms traditional short-duration ambulatory ECG monitoring alone in detecting clinically significant arrhythmias.
By empowering patients to capture medical-grade recordings on-demand during symptomatic episodes, the KM6L device achieved an overall diagnostic yield nearly double that of standard clinical monitoring modalities.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in